Literature DB >> 21678110

Breast tumor characteristics in hormone replacement therapy users.

Jasmina-Ziva Cerne1, Snjezana Frkovic-Grazio, Ksenija Gersak.   

Abstract

The aim of this study was to further elucidate the influence of HRT use, regarding duration, regimen and route of administration, on breast tumor characteristics. We evaluated the associations between HRT use and breast tumor characteristics in 530 postmenopausal women diagnosed with invasive breast cancer. Detailed information on HRT use and mammographic attendance were collected through a postal questionnaire. Adjusted odds ratios and 95% confidence intervals were calculated using logistic regression. Tumors in HRT users were significantly smaller, more often of ductal histologic type and with lower grade and lower mitotic index compared to tumors in nonusers. Tumor characteristics did not vary significantly by HRT duration, regimen and route of administration, except for mitotic index, which was more often of score 2 in long-term users, and of score 3 in short-term users. Higher mammographic surveillance among HRT users did not explain our results. We conclude that tumors in HRT users have a more favorable prognostic profile regardless of duration, regimen and route of administration. These effects seem to be due to the influence of HRT on preexisting tumors causing their greater differentiation rather than earlier detection due to mammographic surveillance.

Entities:  

Mesh:

Year:  2011        PMID: 21678110     DOI: 10.1007/s12253-011-9403-x

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  25 in total

1.  Hormone replacement therapy and accuracy of mammographic screening.

Authors:  A M Kavanagh; H Mitchell; G G Giles
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

2.  The influence of hormone replacement therapy on the pathology of breast cancer.

Authors:  N Biglia; L Sgro; E Defabiani; G De Rosa; R Ponzone; D Marenco; P Sismondi
Journal:  Eur J Surg Oncol       Date:  2005-06       Impact factor: 4.424

Review 3.  Hormone replacement therapy and the sensitivity and specificity of breast cancer screening: a review.

Authors:  E Banks
Journal:  J Med Screen       Date:  2001       Impact factor: 2.136

4.  Type and duration of exogenous hormone use affects breast cancer histology.

Authors:  Anjali S Kumar; Elizabeth Cureton; Veronica Shim; Theadora Sakata; Dan H Moore; Christopher C Benz; Laura J Esserman; E Shelley Hwang
Journal:  Ann Surg Oncol       Date:  2006-11-14       Impact factor: 5.344

Review 5.  Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought.

Authors:  Leon Speroff
Journal:  Menopause       Date:  2008 Mar-Apr       Impact factor: 2.953

6.  Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.

Authors:  Wendy Y Chen; Susan E Hankinson; Stuart J Schnitt; Bernard A Rosner; Michelle D Holmes; Graham A Colditz
Journal:  Cancer       Date:  2004-10-01       Impact factor: 6.860

7.  Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer.

Authors:  P Bonnier; F Bessenay; A J Sasco; B Beedassy; C Lejeune; S Romain; C Charpin; L Piana; P M Martin
Journal:  Int J Cancer       Date:  1998-06-19       Impact factor: 7.396

8.  The impact of hormone replacement therapy on the detection and stage of breast cancer.

Authors:  Julie Cheek; Judith Lacy; SuEllen Toth-Fejel; Katherine Morris; Kristine Calhoun; Rodney F Pommier
Journal:  Arch Surg       Date:  2002-09

9.  Hormone replacement therapy in relation to breast carcinoma incidence rate ratios: a prospective Danish cohort study.

Authors:  Anne Tjønneland; Jane Christensen; Birthe L Thomsen; Anja Olsen; Kim Overvad; Marianne Ewertz; Lene Mellemkjaer
Journal:  Cancer       Date:  2004-06-01       Impact factor: 6.860

10.  Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy.

Authors:  C Stahlberg; A T Pedersen; Z J Andersen; N Keiding; Y A Hundrup; E B Obel; S Møller; F Rank; B Ottesen; E Lynge
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

View more
  1 in total

1.  KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study.

Authors:  Jasmina-Ziva Cerne; Vida Stegel; Ksenija Gersak; Srdjan Novakovic
Journal:  BMC Cancer       Date:  2012-03-22       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.